| 1 |
35244188 | DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions. | 2022 Apr |
1 |
| 2 |
34638417 | Optimization and Validation of a Novel Three-Dimensional Co-Culture System in Decellularized Human Liver Scaffold for the Study of Liver Fibrosis and Cancer. | 2021 Sep 30 |
2 |
| 3 |
34785656 | The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib. | 2021 Nov 16 |
3 |
| 4 |
32670862 | Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma. | 2020 |
1 |
| 5 |
33023006 | STAT3 Mediated miR-30a-5p Inhibition Enhances Proliferation and Inhibits Apoptosis in Colorectal Cancer Cells. | 2020 Oct 3 |
2 |
| 6 |
30761258 | Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma. | 2019 Feb |
2 |
| 7 |
27364975 | Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis. | 2016 Jul 1 |
2 |
| 8 |
26476076 | Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer. | 2015 Sep |
1 |
| 9 |
25071018 | SHP-1 is a target of regorafenib in colorectal cancer. | 2014 Aug 15 |
5 |
| 10 |
25248379 | STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma. | 2014 Nov 15 |
6 |